(MedPage Today) — Zenocutuzumab (Bizengri), a bispecific antibody against HER2 and HER3, showed efficacy in patients with advanced NRG1 fusion-positive cancers, particularly non-small cell lung cancer (NSCLC) and pancreatic cancer, according to…
Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/114096
Author :
Publish date : 2025-02-05 22:00:00
Copyright for syndicated content belongs to the linked Source.
